Month: May 2011

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results

CRANBURY, N.J., May 16, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its third quarter ended March 31, 2011. Recent Highlights Following a meeting with the U.S. Food and Drug Administration (FDA), Palatin …

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results Read More »

Palatin Technologies, Inc. March 31, 2011 Quarter Results; Teleconference and Webcast to be Held on May 16, 2011

CRANBURY, N.J., May 12, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will host a conference call and webcast on May 16, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended March 31, 2011 financial results and its programs, focusing on the upcoming start of its Phase 2 clinical trial with bremelanotide …

Palatin Technologies, Inc. March 31, 2011 Quarter Results; Teleconference and Webcast to be Held on May 16, 2011 Read More »

Palatin Technologies, Inc. Announces Results of Annual Stockholders’ Meeting

CRANBURY, N.J., May 11, 2011 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, held its annual meeting of stockholders today in Cranbury, N.J.  Four proposals were submitted to, and approved by, stockholders. Stockholders approved an increase in authorized …

Palatin Technologies, Inc. Announces Results of Annual Stockholders’ Meeting Read More »

Scroll to Top